Syros Pharmaceuticals, Inc. (SYRS): Modelo de negócios Canvas [Jan-2025 Atualizado]

A Syros Pharmaceuticals, Inc. (SYRS) está revolucionando a paisagem da biotecnologia com sua abordagem terapêutica inovadora na regulação genética, posicionando -se na vanguarda do medicamento de precisão. Ao alavancar uma sofisticada plataforma de controle de genes proprietários, a empresa é pioneira em tratamentos inovadores que visam cânceres desafiadores e distúrbios genéticos com precisão molecular sem precedentes. Seu modelo de negócios exclusivo representa uma fusão ousada de pesquisa genômica avançada, parcerias estratégicas e desenvolvimento terapêutico transformador, prometendo remodelar como entendemos e combate doenças genéticas complexas.

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: Parcerias -chave

Instituições de pesquisa acadêmica

A Syros Pharmaceuticals mantém parcerias estratégicas com as seguintes instituições de pesquisa acadêmica:

Instituição	Foco na pesquisa	Status de colaboração
Instituto de Câncer Dana-Farber	Regulação de genes em oncologia	Parceria ativa
Instituto de Tecnologia de Massachusetts (MIT)	Pesquisa genômica	Colaboração em andamento

Colaboradores farmacêuticos

A Syros estabeleceu as principais parcerias farmacêuticas para ensaios clínicos e descoberta de medicamentos:

• Bristol Myers Squibb - Contrato de colaboração assinado em 2022
• Roche Pharmaceuticals - Parceria de Pesquisa Estratégica

Investidores estratégicos

A Syros Pharmaceuticals garantiu investimentos das seguintes empresas de capital de risco:

Investidor	Valor do investimento	Ano
Pioneiro principal	US $ 45 milhões	2021
Consultores orbimed	US $ 35 milhões	2020

Organizações de pesquisa contratada

Syros colabora com vários CROs para o desenvolvimento clínico:

• IQVIA - Gerenciamento de ensaios clínicos
• Parexel International - Serviços de Desenvolvimento de Medicamentos
• PPD (Perceptive Diagnostics) - Suporte da pesquisa clínica

Investimentos totais de parceria: US $ 80 milhões

Número de colaborações de pesquisa ativa: 7

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: Atividades -chave

Regulação de genes Pesquisa e desenvolvimento terapêuticos

A partir do quarto trimestre de 2023, a Syros Pharmaceuticals investiu US $ 86,4 milhões em despesas de pesquisa e desenvolvimento, focadas especificamente na terapêutica da regulação de genes.

Área de foco de pesquisa	Valor do investimento (2023)	Estágio de pesquisa
Terapêutica de regulação de genes	US $ 86,4 milhões	Desenvolvimento avançado
Plataformas de controle de genes do câncer	US $ 42,3 milhões	Pré -clínico/clínico

Descoberta de medicamentos pré -clínicos e clínicos

A Syros mantém um pipeline de descoberta de medicamentos ativa com vários candidatos em vários estágios de desenvolvimento.

• Total de candidatos a drogas ativas: 6
• Candidatos de estágio pré -clínico: 3
• Candidatos de estágio clínico: 3
• Tempo médio de desenvolvimento por candidato: 4-6 anos

Desenvolvimento de novos tratamentos para câncer e doenças genéticas

A empresa se concentra no desenvolvimento de terapias direcionadas com mecanismos moleculares específicos.

Categoria de doença	Número de programas ativos	Status de desenvolvimento atual
Oncologia	4	Fase 1/2 ensaios clínicos
Doenças genéticas	2	Pesquisa pré -clínica

Condução de pesquisa molecular e genética avançada

A Syros emprega metodologias avançadas de pesquisa com pessoal científico especializado.

• Equipe total de pesquisa: 127 cientistas
• Pesquisadores no nível de doutorado: 68
• Instalações de pesquisa: 2 laboratórios dedicados de biologia molecular
• Investimento anual de equipamentos de pesquisa: US $ 5,2 milhões

Plataformas de controle de genes proprietários que avançam

A empresa desenvolveu plataformas especializadas em tecnologia de controle de genes.

Tecnologia da plataforma	Status de patente	Áreas de aplicação em potencial
SY-5609	Patenteado	Oncologia
SY-1425	Patenteado	Distúrbios genéticos

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: Recursos -chave

Tecnologia proprietária de plataforma de controle de genes

Syros Pharmaceuticals desenvolveu um Plataforma de controle de genes focado no entendimento dos mecanismos de regulação de genes.

Componente de tecnologia	Detalhes específicos
Nome da plataforma	Synrg (genômica reguladora do ácido nucleico de Syros)
Aplicações de patentes	12 Famílias de patentes ativas a partir de 2023
Investimento em pesquisa	US $ 24,7 milhões gastos em P&D em 2022

Portfólio de propriedade intelectual na regulamentação de genes

• 12 famílias de patentes que cobrem tecnologias de controle de genes
• Acordos de licenciamento exclusivos com instituições de pesquisa
• Algoritmos proprietários para análise de expressão gênica

Equipe de pesquisa científica com experiência em genômica

Composição da equipe	Número
Pessoal de pesquisa total	87 funcionários
Pesquisadores de doutorado	62 pesquisadores
Especialistas em genômica	45 cientistas especializados

Instalações avançadas de pesquisa de biologia molecular

Infraestrutura de pesquisa localizada em Cambridge, Massachusetts.

Especificação da instalação	Detalhes
Espaço total de laboratório	22.000 pés quadrados
Investimento em equipamentos de pesquisa	US $ 7,3 milhões em equipamentos de biologia molecular especializados
Plataformas de sequenciamento genômico	3 sistemas de sequenciamento de alto rendimento

Capacidades de desenvolvimento clínico

• 3 programas terapêuticos ativos em estágio clínico
• Oncologia e foco de doença genética
• Infraestrutura de gerenciamento de ensaios clínicos

Métricas de desenvolvimento clínico	2023 dados
Ensaios clínicos ativos	4 ensaios em andamento
Gasto de desenvolvimento clínico	US $ 41,2 milhões em 2022
Capacidade de inscrição do paciente	Ensaios múltiplos de fase I/II

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: proposições de valor

Abordagem terapêutica de regulação genética inovadora

Syros Pharmaceuticals se concentra em regulação de genes terapêutica direcionada ao controle transcricional. A partir do quarto trimestre 2023, o pipeline de pesquisa da empresa se concentra no desenvolvimento de tratamentos que modulam a expressão gênica.

Área de foco de pesquisa	Estágio atual	Indicação de alvo potencial
Regulação transcricional	Desenvolvimento pré -clínico/clínico	Câncer, distúrbios genéticos
SY-5609 Molécula pequena	Fase 1/2 ensaios clínicos	Tumores sólidos avançados

Tratamentos potenciais direcionados para cânceres difíceis de tratar

A Syros desenvolveu estratégias terapêuticas direcionadas, abordando especificamente tipos desafiadores de câncer.

• SY-5609: Inibidor de CDK7 direcionando tumores sólidos avançados
• TAMIBAROTENE: tratamento mielóide agudo (AML) Tratamento
• Abordagens de oncologia de precisão focadas em populações de pacientes geneticamente definidos

Medicina de precisão direcionando mecanismos genéticos específicos

Plataforma terapêutica	Mecanismo genético	Status de desenvolvimento
Plataforma de controle de genes	Regulação transcricional	Pesquisa em andamento
Identificação do motorista genético	Perfil genômico do câncer	Fase avançada de descoberta

Novas estratégias terapêuticas para distúrbios genéticos

O Syros investiga abordagens inovadoras para enfrentar os desafios do transtorno genético por meio da modulação transcricional.

• Tecnologias proprietárias de regulação de genes
• Plataformas de análise genômica computacional
• Estratégias de intervenção terapêutica direcionadas

Desenvolvimento de tratamento personalizado usando idéias genômicas avançadas

Área de insight genômica	Tecnologia usada	Aplicação potencial
Perfil transcricional	Sequenciamento avançado	Oncologia de precisão
Análise da variante genética	Algoritmos de aprendizado de máquina	Terapêutica direcionada

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: Relacionamentos do cliente

Engajamento direto com a comunidade de pesquisa médica

A partir do quarto trimestre 2023, os Syros Pharmaceuticals mantiveram o envolvimento direto por meio de:

Tipo de engajamento	Freqüência	Público -alvo
Pesquisa on -line	4 por ano	Pesquisadores de oncologia
Reuniões do Conselho Consultivo Científico	2 por trimestre	Especialistas em hematologia líder

Colaboração com parceiros de desenvolvimento farmacêutico

Métricas atuais de parceria farmacêutica:

• Parcerias ativas: 3 empresas farmacêuticas
• Acordos totais de pesquisa colaborativa: US $ 12,5 milhões em 2023
• Duração da parceria: média de 2,5 anos

Abordagem de desenvolvimento terapêutico focado no paciente

As estratégias de envolvimento do paciente incluem:

Canal de interação do paciente	Alcance anual
Programas de apoio ao paciente	1.200 pacientes
Sessões de informações sobre ensaios clínicos	250 participantes

Conferência Científica e Participação de Eventos da Indústria

Dados de envolvimento da conferência para 2023:

• Total de conferências participadas: 7
• Apresentações entregues: 12
• Apresentações científicas de pôsteres: 5

Comunicação transparente sobre o progresso da pesquisa

Métricas de transparência de comunicação:

Canal de comunicação	Freqüência	Alcance do público
Atualizações trimestrais de pesquisa	4 vezes por ano	3.500 partes interessadas
Chamadas de relações com investidores	4 vezes por ano	250 investidores

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: canais

Comunicações científicas diretas

A Syros Pharmaceuticals utiliza estratégias de comunicação científica direcionadas com os seguintes canais:

Canal de comunicação	Público -alvo	Freqüência
Comunicações de email direto	Pesquisadores de oncologia	Atualizações trimestrais
Briefings científicos personalizados	Investigadores clínicos	Conforme necessário

Conferências da indústria de biotecnologia e farmacêutica

Detalhes da participação na conferência:

• Reunião Anual da Associação Americana de Pesquisa do Câncer (AACR)
• Congresso da Sociedade Europeia de Oncologia Médica (ESMO)
• Conferência Mundial da Medicina de Precisão

Publicações científicas revisadas por pares

Métricas de publicação para 2023:

Tipo de publicação	Número de publicações
Artigos de periódicos revisados ​​por pares	7
Resumos da Conferência Científica	12

Comunicações de Relações com Investidores

Canais de comunicação de investidores:

• Chamadas de ganhos trimestrais
• Reuniões anuais de acionistas
• Decks de apresentação do investidor
• Sec Comunicação de arquivamento

Plataformas de recrutamento de ensaios clínicos

Estratégias de recrutamento de ensaios clínicos:

Plataforma de recrutamento	Número de ensaios ativos
ClinicalTrials.gov	5 ensaios ativos
Parcerias de rede hospitalar	12 redes de parceria

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: segmentos de clientes

Centros de tratamento oncológicos

Os Syros Pharmaceuticals têm como alvo centros especializados de tratamento de oncologia, focados em terapias de câncer baseadas em genéticas. A partir do quarto trimestre 2023, o segmento de clientes principal da empresa inclui:

Tipo de centro	Número estimado	Alcance potencial do mercado
Centros abrangentes de câncer	51 centros projetados por NCI	87% dos ensaios clínicos de câncer avançado
Centros de Oncologia Genética Especializada	37 centros especializados	62% focados na pesquisa genética do câncer

Instituições de pesquisa de doenças genéticas

Syros se concentra em instituições de pesquisa especializadas em distúrbios genéticos:

• Institutos Nacionais de Saúde (NIH) Programas de Pesquisa Genética
• Os 25 principais centros de pesquisa médica acadêmica
• Fundamentos privados de pesquisa genética

Tipo de instituição de pesquisa	Número de clientes em potencial	Orçamento de pesquisa anual
Instituições de pesquisa acadêmica	128 grandes centros de pesquisa	US $ 3,2 bilhões em financiamento de pesquisa genética

Empresas farmacêuticas

A Syros tem como alvo as empresas farmacêuticas interessadas em desenvolvimento terapêutico baseado em genéticos:

Categoria da empresa	Número de parceiros em potencial	Valor potencial de colaboração
Grandes empresas farmacêuticas	22 empresas farmacêuticas de primeira linha	US $ 450 milhões em potencial valor de colaboração
Empresas de biotecnologia	87 empresas de biotecnologia especializadas	US $ 210 milhões em potenciais investimentos em parceria

Laboratórios de Pesquisa Acadêmica

Syros colabora com laboratórios de pesquisa acadêmica especializados em pesquisa genética:

• Universidades de pesquisa de primeira linha
• Departamentos de pesquisa genética
• Laboratórios de Medicina Translacional

Tipo de laboratório	Número de potenciais colaboradores	Foco na pesquisa
Laboratórios de pesquisa genética	216 laboratórios especializados	Medicina de precisão e regulação de genes

Grupos de pacientes com condições genéticas específicas

Syros identifica grupos de pacientes para terapias genéticas direcionadas:

Condição genética	População estimada de pacientes	Mercado de tratamento potencial
Câncer de ovário	22.280 novos casos anualmente	US $ 780 milhões em potencial mercado
Leucemia	60.530 novos casos anualmente	Mercado potencial de US $ 1,2 bilhão

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: estrutura de custos

Despesas de pesquisa e desenvolvimento

Para o ano fiscal de 2023, a Syros Pharmaceuticals registrou despesas totais de pesquisa e desenvolvimento de US $ 95,3 milhões.

Ano	Despesas de P&D	Porcentagem do total de despesas
2023	US $ 95,3 milhões	68.4%
2022	US $ 110,5 milhões	71.2%

Custos de gerenciamento de ensaios clínicos

As despesas de ensaios clínicos para a Syros Pharmaceuticals em 2023 foram de aproximadamente US $ 42,7 milhões.

• Ensaios clínicos de fase 1: US $ 18,2 milhões
• Ensaios clínicos de fase 2: US $ 24,5 milhões

Proteção à propriedade intelectual

Propriedade intelectual e despesas relacionadas a patentes em 2023 totalizaram US $ 3,6 milhões.

Categoria de custo de IP	Quantia
Registro de patentes	US $ 2,1 milhões
Manutenção de patentes	US $ 1,5 milhão

Compensação de pessoal científico

As despesas totais de pessoal para a equipe científica em 2023 foram de US $ 52,4 milhões.

• Salários base: US $ 38,6 milhões
• Compensação baseada em ações: US $ 9,2 milhões
• Benefícios e outras compensações: US $ 4,6 milhões

Manutenção de infraestrutura de tecnologia

Os custos de manutenção de tecnologia e infraestrutura para 2023 foram de US $ 7,2 milhões.

Categoria de custo de infraestrutura	Quantia
Equipamento de laboratório	US $ 4,5 milhões
Sistemas de TI	US $ 2,7 milhões

Syros Pharmaceuticals, Inc. (SYRS) - Modelo de negócios: fluxos de receita

Potenciais acordos futuros de licenciamento de medicamentos

A partir do quarto trimestre 2023, a Syros Pharmaceuticals não possui acordos ativos de licenciamento de medicamentos gerando receita.

Parcerias de colaboração de pesquisa

Parceiro	Tipo de colaboração	Detalhes financeiros
Bristol Myers Squibb	Colaboração de pesquisa	Pagamento inicial de US $ 50 milhões em 2020

Pagamentos marcantes de parceiros farmacêuticos

Os pagamentos em potencial da Bristol Myers Squibb Collaboration, com valores específicos de marcos não divulgados publicamente.

Vendas potenciais de produtos terapêuticos

Não há vendas atuais de produtos terapêuticos a partir de 2024. Produtos de pipeline em desenvolvimento:

• SY-5609 (inibidor de CDK)
• SY-1425 (terapia direcionada)

Subsídios do governo e de pesquisa privada

Fonte de concessão	Quantia	Ano
Institutos Nacionais de Saúde (NIH)	US $ 1,4 milhão	2022

Receita total da Syros Pharmaceuticals em 2022: US $ 34,7 milhões

Caixa e equivalentes em dinheiro a partir do terceiro trimestre 2023: US $ 94,8 milhões

Syros Pharmaceuticals, Inc. (SYRS) - Canvas Business Model: Value Propositions

You're looking at the core value Syros Pharmaceuticals, Inc. (SYRS) brings to the table-it's all about precision medicine driven by their gene control platform. The value proposition isn't just a drug; it's a novel way to attack diseases by modulating gene expression, which is a significant differentiator in oncology.

Novel approach to drug discovery by modulating gene expression (RAR$\alpha$ agonist).

The fundamental value is the proprietary gene control platform. This technology integrates genomics and chemical biology to target previously undruggable noncoding regions of the genome that drive disease. This approach aims to convert those hard-to-target gene drivers into precise medicines. For instance, the lead candidate, Tamibarotene, is an oral, selective retinoic acid receptor alpha (RAR$\alpha$) agonist, which directly addresses a specific genetic dependency in certain cancers.

Potential for new targeted therapies for hematologic malignancies.

The primary value centers on offering new standards of care for hematologic malignancies, specifically targeting patient subsets defined by molecular biomarkers. This precision is key to maximizing clinical benefit. The market potential here is substantial, reflecting a strong unmet need for targeted, well-tolerated options, especially for patients who cannot tolerate standard high-intensity chemotherapy.

Here's a look at the market opportunity that this targeted approach addresses:

Indication Segment	Metric	Value	Source Year/Estimate
Higher-Risk MDS (U.S.)	Total Market Opportunity	$1.6 billion	By 2029
Tamibarotene Potential Capture (HR-MDS)	Estimated Potential Revenue	Over $800 million
RARA-positive AML (Phase 2 Trial)	Complete Remission (CR) Increase (with standard therapy)	48%

Oral selective retinoic acid receptor alpha (RAR$\alpha$) agonist mechanism.

The mechanism itself is a core value driver. Tamibarotene, as an oral selective RAR$\alpha$ agonist, offers a convenient dosing route compared to intravenous treatments. The clinical data, such as the positive signals from the SELECT-AML-1 Phase 2 trial showing a 100% CR/CRi rate in a specific population, underscore the value of this mechanism in RARA-positive AML and HR-MDS. This focus on a specific genetic driver, RARA overexpression, allows for a highly focused development and commercial strategy.

Remaining deprioritized assets (e.g., SY-5609) available for partnering.

Even as the company focuses on its lead asset, the pipeline contains other valuable, de-risked assets that represent potential non-dilutive value through partnerships. SY-5609, a cyclin-dependent kinase 7 (CDK7) inhibitor, is one such asset. It has already achieved Orphan Drug Designation from the FDA for pancreatic cancer. This designation is a tangible value-add, offering market exclusivity incentives. While the company's strategic focus may shift, these assets provide optionality for collaboration or divestiture, helping to manage the burn rate. For context on the financial environment supporting this strategy, consider the recent operating metrics:

• Cash and cash equivalents as of September 30, 2024: $58.3 million.
• Anticipated cash runway extending into Q3 2025.
• Net Loss for Q3 2024: $6.4 million (or $0.16 per share).
• Annual Accounts Payable (latest reported): $11.544M.

The value here is the ability to maintain operations through critical data readouts while potentially offloading development costs for secondary assets. Honestly, managing that cash runway is a huge part of the near-term value proposition for investors.

Syros Pharmaceuticals, Inc. (SYRS) - Canvas Business Model: Customer Relationships

You're dealing with the aftermath of a pivotal trial failure and a subsequent corporate restructuring, so the nature of customer relationships for Syros Pharmaceuticals, Inc. shifts dramatically from growth-focused engagement to preservation and wind-down management.

High-touch engagement with institutional investors for capital raising

The most recent significant capital raising activity involved securing gross proceeds of approximately $45.0 million via an underwritten offering of common stock and pre-funded warrants, which closed on or about December 21, 2023. This historical engagement was crucial for funding operations, with cash reserves projected to last into the third quarter of 2025 based on September 30, 2024, figures of $58.3 million.

Investor engagement in late 2025 is characterized by managing the fallout from the delisting and the wind-down strategy. Institutional investors saw significant position reductions, with firms like BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC removing 2,750,151 shares (-100.0%) in Q1 2025.

Direct communication with regulatory bodies (FDA) for clinical programs

Direct engagement with the U.S. Food and Drug Administration (FDA) centered on advancing tamibarotene. The FDA had granted Fast Track Designation for tamibarotene in the treatment of Unfit AML and previously for HR-MDS in January 2023. However, the primary relationship focus shifted following the failure of the SELECT-MDS-1 Phase 3 trial in November 2024, which did not meet its primary endpoint.

Communication post-trial failure would involve discussions related to the discontinuation of the SELECT-AML-1 Phase 2 trial and the wind-down plan, which was approved by the Board of Directors to limit expenditures under a budget approved by the secured lender.

Managing relationships with creditors due to loan default status

The failure of the SELECT-MDS-1 trial on November 2024 constituted an event of default under the secured loan facility with Oxford Finance LLC. This triggered a need for immediate, high-stakes management with the creditor. Syros Pharmaceuticals entered an agreement on February 28, 2025, to settle all outstanding debt obligations to Oxford Finance LLC for approximately $6 million, paid via a mix of cash and non-cash assets. This settlement satisfied all debts, though the default could have accelerated repayment of $43.6 million. As part of the agreement, Oxford received a first priority security interest in all intellectual property and Syros agreed to a wind-down budget.

Transparent communication with shareholders during delisting process

Shareholder communication was dominated by the decision to voluntarily delist from the Nasdaq Stock Market, effective on or about March 20, 2025. This followed the company notifying Nasdaq of its intention to file a Form 25 on or about March 10, 2025. The company cited non-compliance with listing standards, including the bid price closing below $1.00 per share for more than 35 consecutive business days. Following delisting, the intent was to file a Form 15 around March 20, 2025, to suspend reporting obligations under the Exchange Act, with deregistration expected 90 days after the Form 15 filing.

The company's stock price fell precipitously, trading at $0.14 on February 28, 2025, and dropping by 44.13% to $0.08 in premarket trading on March 3, 2025.

The key relationships and associated financial context are summarized below:

Relationship Focus	Key Metric/Amount	Date/Period Reference
Capital Raising (Historical)	Gross Proceeds of $45.0 million	December 2023
Creditor Settlement (Oxford Finance)	Settlement Amount of approximately $6 million	February 28, 2025
Loan Default Potential Acceleration	Potential Acceleration of $43.6 million	Post-November 2024 Default
Cash Runway Projection	Expected to fund operations into Q3 2025	Based on September 30, 2024, cash of $58.3 million
Shareholder Communication (Delisting)	Stock price reached $0.08 in premarket trading	March 3, 2025

The company's operational focus shifted to an orderly wind-down, which involved a 94% workforce reduction at one point following the trial failure.

• FDA Fast Track Designation for Tamibarotene in AML.
• Asset transfer of Tamibarotene-related data to Rege Nephro on February 26, 2025.
• Anticipated tax refund of approximately $2.4 million to aid financial strategy.
• The company's market capitalization was reported at $2.2 million around March 2025.

Syros Pharmaceuticals, Inc. (SYRS) - Canvas Business Model: Channels

You're looking at the channels Syros Pharmaceuticals, Inc. (SYRS) used to reach investors and partners as of late 2025, especially after the significant corporate restructuring following the November 2024 trial update. The shift from a public exchange to over-the-counter (OTC) trading fundamentally changed the investor channel.

Direct-to-investor communications via press releases and SEC filings

The primary channel for official corporate and financial updates remains filings with the Securities and Exchange Commission (SEC) and corresponding press releases. You should note the transition away from the regular quarterly/annual filing cadence following the voluntary delisting.

• The company filed an SC 13D/A on 03/27/2025.
• The last reported earnings date available was for Q3 2024, announced on October 31, 2024.
• Cash, cash equivalents and marketable securities as of June 30, 2024, stood at $79.0 million.
• Syros previously believed its cash position would fund operations into the third quarter of 2025.
• Following the November 2024 trial result, loan obligations totaling approximately $43.7 million were declared immediately due, with a partial repayment of $33.5 million made.

Scientific publications and presentations at medical conferences

Scientific communication channels are critical for validating the underlying science to the medical community and potential future partners. These presentations serve as a key non-financial channel for communicating value.

• Syros Pharmaceuticals presented a poster at the SOHO 12th Annual Meeting on September 4, 2024.
• The company planned to host an HR-MDS-focused Webcast Event on June 25, 2024.
• At the time of the September 2024 presentation, the company's market capitalization was reported as $41.02 million.

Nasdaq Stock Market for public trading (prior to March 2025 delisting)

The public exchange channel ceased to be active for Syros Pharmaceuticals in the first quarter of 2025. This was a deliberate move to reduce regulatory costs while conserving cash.

The voluntary delisting from the Nasdaq Stock Market was expected to become effective on or about March 20, 2025, following a Form 25 filing around March 10, 2025.

The non-compliance issues leading to this action included:

• Bid price closing below $1.00 per share for more than 35 consecutive business days.
• Market value of publicly held shares below the minimum $15M requirement for more than 35 consecutive business days.

The stock price on February 28, 2025, closed at $0.14, dropping to $0.08 in premarket trading on March 3, 2025. Current trading is on OTC Markets, where the market cap was recently cited as US$13.4k and the share price at US$0.000547.

Licensing and collaboration agreements for asset monetization

Asset monetization through partnerships is a core channel for non-revenue generating biotech firms. You can see the channel activity has been focused on winding down past deals and exploring new ones for remaining assets.

Key historical and ongoing partnership channel activities include:

Agreement/Asset Status	Counterparty/Asset	Date/Period	Financial Impact/Action
Collaboration Termination	Pfizer	Q2 2023	Resulted in $2.8 million revenue in Q2 2023; $0 revenue in Q1 2024.
Master Collaboration Agreement Termination	QIAGEN Manchester Limited	Notice on November 13, 2024	Agreement from March 7, 2022.
Asset Acquisition	Rege Nephro (for Tamibarotene-related assets)	April 2025	Acquired assets for U.S. clinical trials.
Business Development Exploration	CDK7 inhibitor asset	Late 2025 focus	Exploring opportunities for asset 5609.

The company is actively exploring business development opportunities for the CDK7 inhibitor asset, 5609, as a key monetization channel moving forward.

Syros Pharmaceuticals, Inc. (SYRS) - Canvas Business Model: Customer Segments

Biopharmaceutical companies seeking to acquire or license oncology assets

• US market opportunity cited for Tamibarotene in higher-risk MDS with RARA overexpression: over $800 million.
• Lead product candidate Tamibarotene was in Phase III clinical trial for myelodysplastic syndrome and Phase II for acute myeloid leukemia as of late 2024/early 2025.
• SY-5609, a cyclin-dependent kinase 7 inhibitor, was in a Phase I clinical trial in patients with select advanced solid tumors.
• The company announced a voluntary delisting from Nasdaq and SEC deregistration in February 2025.

Institutional and venture capital investors focused on distressed biotech

The investor base structure as of early 2025 showed specific institutional engagement:

Metric	Value
Total Institutional Investors (Pre-Delisting Context)	22
Institutions Filing 13D/G or 13F Forms (Early 2025)	10
Total Shares Held by Filing Institutions (Early 2025)	904
Analyst Coverage (Late 2024/Early 2025)	4

The financial position leading into the wind-down phase included:

• Cash position at end of Q3 2024: $58.3 million.
• Cash runway guided to fund operations into Q3 2025.
• EBITDA (Last Twelve Months, late 2024 context): -$110.18 million.
• Current Ratio (late 2024 context): 2.25.
• Stock price as of March 19, 2025: $0.12 per share.
• Market capitalization following November 13, 2024 trial news: $5.56 million.

Patients with hematologic malignancies (e.g., AML, MDS) (indirectly)

• Lead candidate Tamibarotene targets RARA-positive patients with higher-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML).
• SY-2101 is being developed for the treatment of acute promyelocytic leukemia (APL).
• The company employed 117 full-time employees as of December 31, 2023.

Academic and clinical research collaborators

• Total Funding raised by Syros Pharmaceuticals, Inc. through its history: $124 million over 7 rounds.
• Largest funding round: Post IPO, $130 million in September 2022.
• Annual Revenue as of December 31, 2023: $9.94 million.
• R&D Expenses reported for Q3 2024: $20.5 million.
• G&A Expenses reported for Q3 2024: $5.7 million.

Syros Pharmaceuticals, Inc. (SYRS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Syros Pharmaceuticals, Inc. (SYRS) as of late 2025, and honestly, the numbers tell a story of intense focus driven by recent, significant financial pressure. The cost structure is dominated by the necessary, high-stakes investment in research and development, coupled with the immediate, sharp costs of a major corporate restructuring.

The primary ongoing operational cost is Research and Development (R&D), which reflects the company's singular focus on advancing tamibarotene. For the third quarter of 2024, R&D expenses were reported at $20.5 million. This was a reduction from $28.3 million in Q3 2023, primarily due to cutting external R&D consulting, contract manufacturing, and headcount reductions. This spending is principally directed toward the advancement of tamibarotene.

General and Administrative (G&A) expenses also saw a reduction, coming in at $5.7 million for Q3 2024, down from $7.8 million the prior year. This decrease was largely driven by lower headcount and related expenses, consulting fees, and facilities costs.

The most dramatic cost event relates to debt and restructuring. Following the failure of the SELECT-MDS-1 Phase 3 trial in November 2024, an event of default was triggered under the loan agreement with Oxford Finance LLC, which initially allowed the lender to declare the repayment of $43.6 million immediately due and payable. This potential liability forced immediate, drastic action.

To manage this, Syros Pharmaceuticals initiated significant workforce reduction and corporate restructuring costs. The response included a drastic workforce reduction of 94% to curb costs and maximize stakeholder value. However, the ultimate financial resolution for the debt was a settlement in early 2025. Here's a quick look at the key cost components and the resulting financial position as of that restructuring period:

Cost Component / Metric	Amount / Value	Period / Date
Research and Development (R&D) Expenses	$20.5 million	Q3 2024
General and Administrative (G&A) Expenses	$5.7 million	Q3 2024
Potential Accelerated Debt Obligation (Upon Default)	$43.6 million	Post-November 2024
Debt Settlement Payment (Cash & Non-Cash Assets)	Approximately $6 million	February 28, 2025
Workforce Reduction Magnitude	94%	Post-Default Restructuring
Cash on Hand (Pre-Settlement Context)	$58.3 million	September 30, 2024

The company's cost-cutting efforts were clearly designed to extend its runway. Based on the cash position as of September 30, 2024, Syros Pharmaceuticals believed its existing cash and cash equivalents would be sufficient to fund anticipated operating expenses and capital expenditure requirements into the third quarter of 2025. The settlement of the debt for approximately $6 million, which included non-cash assets, was a critical step in stabilizing the cost structure following the default event.

The major cost drivers that you need to track going forward are tied to the remaining operational burn rate, which is now significantly leaner due to restructuring. You should keep an eye on these specific areas:

• R&D expenditures, now principally focused on tamibarotene advancement.
• Costs associated with any remaining corporate infrastructure.
• The impact of the 94% workforce reduction on future operational capacity.
• The final cash utilization rate following the debt discharge.

The net loss for Q3 2024 was $6.4 million, a substantial improvement from the $40.1 million net loss in Q3 2023, directly illustrating the impact of reduced operating expenses. Finance: draft 13-week cash view by Friday.

Syros Pharmaceuticals, Inc. (SYRS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Syros Pharmaceuticals, Inc. (SYRS) as of late 2025, and honestly, the picture is one of transition, moving away from past partnerships toward a potential self-commercialization model for tamibarotene. The immediate past shows a significant drop-off in recognized revenue.

For the trailing twelve months ending September 30, 2024, Syros Pharmaceuticals, Inc. recorded a minimal revenue figure. This low number reflects the structural shift in the company's operational focus and prior agreements. Here's a quick look at the most recent hard numbers we have:

Metric	Amount/Period	Notes
Trailing Twelve-Month (TTM) Revenue	$386.00K	As of September 30, 2024.
Q3 2024 Collaboration Revenue	Zero	Compared to $3.8 million in Q3 2023.
Reason for Zero Collaboration Revenue	Termination of Pfizer collaboration	Reflects the end of the prior partnership.

The zero collaboration revenue in the third quarter of 2024 is a direct consequence of the termination of the collaboration agreement with Pfizer. So, the current revenue generation is not reliant on those prior structures.

One key element that could provide a one-time financial boost relates to the asset divestiture. Syros Pharmaceuticals completed the sale of Tamibarotene-related clinical and non-clinical assets to Rege Nephro Co., Ltd. on February 26, 2025. This transaction included human safety study data for an NDA, contracts with a contract manufacturing organization (CMO), and the Tamibarotene active pharmaceutical ingredient (API) and drug products. While the specific one-time payment amount isn't public, this deal represents a potential, non-recurring revenue event that has already been executed.

Looking forward, the revenue model is heavily weighted toward the potential success of tamibarotene as a frontline treatment for higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression. The company plans for an independent U.S. launch upon NDA approval, which shifts the revenue potential from milestone/royalty structures to direct product sales, though future out-licensing deals remain a possibility for other pipeline assets.

The streams that could materialize from out-licensed programs, should any future deals be struck or existing ones have residual value, include:

• Future milestone payments from successful development or regulatory achievements on out-licensed programs.
• Royalty payments based on net sales of any successfully commercialized, out-licensed products.

To be fair, the current strategy is centered on capturing the full commercial upside of tamibarotene, which has a projected U.S. market opportunity of over $800 million by 2029 for the RARA-overexpressing patient segment alone. Finance: draft the pro-forma revenue model incorporating the Rege Nephro payment by next Tuesday.